my location - advr -jan2004

By: allenadvrlong

25 Jan 2004, 08:47 AM EST

Msg. 136267 of 136422
(This msg. is a reply to 136234 by mind31.)
Jump to msg. #

ADVR-Maybe a little help from our friends at the SEC coming.

By now all of you should know about the new rules on Naked Shorting-I posted it here yesterday.

on 1/6 there was another big write up on the whole NS situation--108 companies were listed with the situation
The forst one on the list was ADVR [my Beloved GDLS was further down}

WE may be in for some better times here nased on the new rules.

Allen

By: allenadvrlong

25 Jan 2004, 08:58 AM EST

Msg. 136271 of 136422
(This msg. is a reply to 136269 by lunker10706.)
Jump to msg. #

Larry--I WILL DO BETTER for you bud.

Give me a few minutes and I will

1- paste the article from 1/6--just read it and YES you
will find ADVR--then

2- I will repost what came out Friday about the new rules
its caught many by surprise--being an ex lawman as you
are, let me compare this new rule coming out like it did
and surprising /stunning many as having the affect of a
"STING" operation

back in a few

Allen

By: allenadvrlong

25 Jan 2004, 09:01 AM EST

Msg. 136272 of 136422
Jump to msg. #

Larry-1 of 2-Here is the Jan 6 04 article--ADVR is listed
----------------------------------------------------------

Skip to message. Skip to access key tips.

Enter symbol:
Message Board Quote(s) LiveChart - - - - - News Chart (1-year) Find symbol

Home | Board Directory | Member Forums | Rules of the Road | My Finance | Portfolios | Help & Feedback

Advanced Plant Pharmaceuticals (BB: APPI)
APPI Quote | APPI Msg Board | APPI LiveCharts | APPI Chart | APPI News | APPI Company Info | APPI I-Watch | APPI Insider | APPI Analyst Recs | APPI Top Holders

« APPI Message list | Reply to msg. | Post new msg. « Older | Newer »
By: sstockboy1
24 Jan 2004, 07:46 PM EST
Msg. 21999 of 22001
Jump to msg. #

StockGate: NASAA in Explosive SEC Comments on Short Sales

Jan 6, 2004 (financialwire.net via COMTEX) -- (FinancialWire) The North American Securities Administrators Association, an organization that has become a key player in regulatory matters since several of its members have charged in to correct market abuses, leaving the U.S. Securities and Exchange Commission to play catch-up, waited until the last day to issue what many observers regard as an explosive commentary and thinly-veiled reminder of its members' potential to step into the "naked short sales" issue that is the subject of the SEC's proposed "Regulation SHO."

The StockGate scandal has enveloped tens of thousands of shareholders, market losses some say are in the billions or even trillions, and at least 200 public companies, including 13 brokers, such as A.G. Edwards, Inc. (NYSE: AGE), Ameritrade Holding Corp. (NASDAQ:AMTD), Deutsche Bank AG (NYSE: DB), and E*Trade Group, Inc. (NYSE: ET), that have been identified by one source or another as either participating in the practice or allowing it to fester.

"NASAA urges the Commission to reconsider its stance regarding the role of the Depository Trust and Clearing Corporation (the DTC). As a threshold matter, NASAA believes that the Commission should explicitly prohibit the DTC from lending more shares of a security than it actually holds. The ability of the overall proposed rule would be severely impared unless the Commission undertakes to implement such a prohibition," stated Ralph Lambiase, NAASA president and Director of the Connecticut Division of Securities.

NAASA represents regulators in all 50 staes, Canada, Mexico, the District of Columbia and Puerto Rico.

Among other things, NAASA's letter could be interpreted as a diplomatic warning to the SEC that some of its member states, represented by fearless regulators such as the Financial Industry's "Person of the Year" for 2003, New York State AG Eliot Spitzer or the Massachusetts Secretary of State, for example.

John Petersen, Esq., a securities attorney, notes that "the real problem with the naked short issue is that non-US brokers, typically in Canada, can use the Canadian counterpart of DTC to cover their naked shorting activities. So in theory anyway, the records of DTC never end up with a record that a Canadian broker is running a large naked short position."

Since NASAA represents Canadian regulators as well, the organization may be in a position to facilitate joint regulatory action that may be needed.

In addition to NASAA's comments about the DTC, the organization:

1. Diplomatically warns the SEC that the states may take up jurisdiction if potential trading abuses are not remedied.

2. Supports proposed written documentation regarding closing out short sale positions.

3. Said it believes the "penalty box" for fails-to-deliver needs to be significantly toughened, extending the restriction on short sales in the same security to short sales in ALL securities until the problem is resolved. It also wants to see suspensions or revocations of licenses for repeat offenders, and mandated buy-ins.

4. Questions "why the Commission proposes to permit significant settlement failures at all."

5. Questions why the SEC would "not extend the proposed bid tests to all securities markets and exchanges," echoing sentiments by many of the Commissioners in the initial go-round with their own staff, in essence suggesting it makes no sense not to extend the "uniform bid test to those markets most affected by naked short selling practices."

6. Questions how the "uniform" bid test as proposed, applied to both market-makers and specialists, benefits the public; and

7. Said it believes that the proposed market maker exemption should not be implemented in a way that it market-makers known by NASAA to engage in "bear raids" can hide behind it.

The letter is available on the web at:

www.nasaa.org/nasaa/Files/File_Uploads/Short Sales Comment.37990-38287.pdf

FinancialWire recently reported that the "London Stock Exchange has embarrassed the United States Securities and Exchange Commission and the NASD with its tough handling of naked short selling involving Room Service (London: RSV). Unlike the SEC and NASD, which have exacted relatively insignificant 'show fines,' but in general have left most of those involved in the practice alone, the LSE has simply ordered market makers involved in the scandal to give investors who did not receive shares their money back."

Comments on Regulation SHO ended Monday.

Some 121 companies, including 13 brokers, such as FleetBoston (NYSE: FBF), Goldman, Sachs & Co. (NYSE: GS), H. Myerson & Co., Inc. (NASDAQ:MHMY), Olde / H&R Block (NYSE: HRB), Charles Schwab (NYSE: SCH), Toronto-Dominion's (NYSE: TD), TD Waterhouse Group and vFinance, Inc. (OTCBB: VFIN). A.G. Edwards, Inc. (NYSE: AGE), Ameritrade Holding Corp. (NASDAQ:AMTD), Deutsche Bank AG (NYSE: DB), and E*Trade Group, Inc. (NYSE: ET), have been embroiled for over a year in a raging controversy

The remaining 108 companies among the 121 named to date have issued press releases or been named in the media as having been victimized, or as taking various actions, either alone or in concert with other companies, to oppose manipulative trading in the form of illegal naked short selling. The actions have ranged from lawsuits to withdrawals and threatened withdrawals from the electronic trading system managed by the Depository Trust & Clearing Corp., to withdrawals from toxic financings, to the issuance of dividends or name changes designed to squeeze manipulators, to joining associations or networks or to contacting regulatory authorities to provide documentation of abuses or otherwise complain.

The complete list of those 108 companies include Advanced Viral Research Corp. (OTCBB: ADVR), AdZone Research, Inc. (OTCBB: ADZR), Amazon Natural Treasures (OTC: ANTD), America's Senior Financial Services (OTCBB: AMSE), American Ammunition, Inc. (OTCBB: AAMI), AngelCiti Entertainment (OTCBB: AGLC), ATSI Communications, Inc. (OTC: ATSC), Federal Agricultural Mortgage / Farmer Mac (NYSE: AGM) Allied Capital (NYSE: ALD), American Motorcycle (OTC: AMCYV), American International Industries (OTCBB: AMIN), Ameri-Dream (OTC: AMDR), Adirondack Pure Springs Mt. Water Co. (OTCBB: APSW), ATSI Communications, Inc. (OTC: ATSC) Bluebook International (OTCBB: BBIC), Blue Industries (OTCBB: BLIIV), Bentley Communications (OTCBB: BTLY), BIFS Technologies Corporation (OTCBB: BIFT), Biocurex (OTCBB: BOCX). Broadleaf Capital Partners, Inc. (OTCBB: BDLF), Chattem, Inc. (NASDAQ:CHTT), Critical Home Care (OTCBB: CCLH), Composite Holdings (OTC: COHIA), CyberDigital, Inc. (OTCBB: CYBD). Diamond International Group (OTCBB: DMND), Dobson Communications Corp. (NASDAQ:DCEL), Eagle Tech Communications (OTC: EATC), Edgetech Services (OTCBB: EDGH);

Also, Endovasc Ltd. (OTCBB: EVSC), Enviro-Energy Corporation (OTCBB: ENGY), Environmental Products & Technologies (OTC: EPTC), Environmental Solutions Worldwide, Inc. (OTCBB: ESWW), EPIXTAR Corp. (OTCBB: EPXR), eResearchTechnologies, Inc. (NASDAQ:ERES), Flight Safety Technologies (OTCBB: FLST), Freddie Mac (NYSE: FRE), FreeStar Technologies (OTCBB: FSRCE), Geotec Thermal Generators, Inc. (OTCBB: GETC), Genesis Intermedia (OTC: GENI), GeneMax Corp. (OTCBB: GMXX), Global Explorations Inc (OTC: GXXL), Global Path (OTCBB: GBPI), GloTech Industries, Inc. (OTCBB: GTHI), Green Dolphin Systems (OTCBB: GLDS), Group Management (OTCBB: GPMT), Hop-On (OTC: HPON), H-Quotient, Inc., (OTCBB: HQNT), Hyperdynamics Corp. (OTCBB: HYPD), International Biochem (OTCBB: IBCL), Intergold Corp. (OTCBB: IGCO), International Broadcasting Corporation (OTCBB: IBCS), InternetStudios, Inc. (OTCBB: ISTO), ITIS Holdings (OTCBB: ITHH), Investco Corp. (OTCBB: IVCO), Lair Holdings (OTC: LAIR), Lifeline BioTechnologies Inc. (OTC: LBTT), Life Energy & Technology (OTCBB: LETH), MBIA (NYSE: MBI);

Also, MegaMania Interactive (OTC: MNIA), MetaSource Group, Inc. (OTCBB: MTSR), Midastrade.com (OTC: MIDS), Make Your Move (OTCBB: MKMV), Medinah Minerals (OTC: MDMN), MSM Jewelry Corp. (OTC: MSMC), Nanopierce Technologies, Inc. (OTCBB: NPCT), Nutra Pharmaceutical (OTCBB: NPHC), Nutek (OTCBB: NUTK), Navigator Ventures (OTC: NVGV), Orbit E-Commerce, Inc. (OTCBB: OECI), Pitts & Spitts (OTC: PSPP), Sales OnLine Direct (OTCBB: PAID), Pacel Corp. (OTCBB: PACC), PayStar Corporation (OTC: PYST), Petrogen Corp. (OTCBB: PTGC), Pinnacle Business Management (OTC: PCBM), Premier Development & Investment, Inc. (OTCBB: PDVN), PrimeHoldings.com, Inc. (OTC: PRIM), Phlo Corporation (OTCBB: PHLC), Resourcing Solutions (OTC: RESG), Reed Holdings (OTC: RDHC), Rocky Mountain Energy Corp. (OTCBB: RMECE), RTIN Holdings (OTCBB: RTNHE), Saflink Corp. (NASDAQ:SFLK), Safe Travel Care (OTCBB: SFTVV), Sedona Corp. (OTCBB: SDNA);

Also, Sionix Corp. (OTCBB: SINX), Sonoran Energy (OTCBB: SNRN), Starmax Technologies (OTC: SMXIF), Storage Suites America (OTC: SSUA), Suncomm Technologies (OTC: STEH), Sports Resorts International (NASDAQ:SPRI), Technology Logistics (OTC: TLOS), Swiss Medica, Inc. (OTCBB: SWME), Ten Stix, Inc. (OTCBB: TNTI), Tidelands Oil (OTCBB: TIDE), Titan Construction (OTC: TTCS), Trezac Corp. (OTCBB: TRZAV), Universal Express, Inc. (OTCBB: USXP), Valesc Holdings, Inc. (OTCBB: VLSHV), Vega Atlantic (OTCBB: VGAC), Viragen (AMEX: VRA), Viragen International (OTCBB: VGNI), Vista Continental Corporation, (OTCBB: VICC), Viva International (OTCBB: VIVI), Vtex Energy (OTCBB: VXENE) and Wizzard Software (OTCBB: WIZD), WorldTradeShow.com (OTC: WTSW) and Y3K Secure Enterprise Software, Inc. (OTCBB: YTHK).

Earlier in 2003, the SEC fined Rhino Advisors, Inc., $1 million for its representation of Amro International in the financing and manipulation of Sedona Corp. Amro, also known as AMRO, was registered in Panama, a secretive offshore haven, but was not named in the SEC settlement. Another 60 public companies may have been manipulated by the fined Rhino Advisors and its indicted principals, or its funding apparatus, Amro.

These include:

All American Food Group Inc (OTC: AAFGQ), Amanda Co Inc (OTC: AMNA), Antra Holdings (OTC: RECD), Aquis Communications Group Inc (OTCBB: AQUIS), Avanir Pharmaceuticals (AMEX: AVN), Bionutrics Inc (OTC: BNRX), Brilliant Digital Entertainment Inc (AMEX: BDE), Bravo! Foods International Corp. (OTCBB: BRVOE), Butler National Corp (NASDAQ: BUTL), Calypte Biomedical Corp (OTCBB: CYPT), Chemtrak Inc/DE (OTC: CMTR), Clicknsettle Com Inc (OTCBB: CLIK), Corporate Vision Inc (OTC: CVIA), Crown Laboratories Inc/DE (OTC: CLWB), Dental Medical Diagnostic Systems Inc (OTC: DMDS), Detour Media Group Inc (OTC: DTRM),

Also, Digital Privacy Inc/DE (OTC: DGPV), Senior Services Inc (OTC: DISS), International Inc (OTC: DYNX), Endovasc Ltd Inc (OTCBB: EVSC), Esynch Corp/CA (OTCBB: ESYN), Focus Enhancements Inc (NASDAQ: FSCE), Frederick Brewing Co (OTC: FRBW), Greystone Digital Technology Inc (OTC: GSTN), Havana Republic Inc/FL (OTCBB: HVNR), Henley Healthcare Inc (OTC: HENL), Hollywood Media Corp (NASDAQ: HOLL), Ibiz Technology Corp (OTCBB: IBZT), Diagnostic Systems Inc/FL (OTCBB: IMDS), Imaging Technologies (OTCBB: IMTO), Integrated Surgical Systems Inc (OTCBB: RDOC),

Also, Interferon Sciences Inc (OTC: IFSC), Interiors Inc (OTC: ITRNA), Laminaire Corp (OTC: THMZ), Medisys Technologies Inc (OTC: SCEP), Milestone Scientific Inc/NJ (AMEX: MS), Nevada Manhattan Group Inc (OTC: NVMH), Innovations Inc (OTCBB: NTGE), Systems Group (OTC: OSYM), Pacific Systems Control Technology Inc (OTCBB: PFSY), Professional Transportation Group Ltd Inc (OTC: TRUC), Rnethealth Inc (OTC: RNTT),

Also, Sand Technology Inc (NASDAQ: SNDT), Sedona Corp (OTCBB: SDNA), Silverado Foods Inc (OTC: SVFO), Stockgroup Information Systems (OTCBB: SWEB) Surgilight Inc (OTC: SRGL), Tasty Fries Inc (OTCBB: TFRY), Tech Laboratories Inc (OTCBB: TCHL), Teltran International Group Ltd (OTC: TLTG), Titan Motorcycle Co of America Inc (OTC: TMOTQ), Trans Energy Inc (OTCBB: TSRG), Motorcycle Co (OTC: UMCC), Universal Communication Systems Inc (OTCBB: UCSY), Medical Systems Inc (OTC: UMSI), Vianet Technologies Inc (OTC: VNTK),Viragen Inc (AMEX: VRA), Webcatalyst Inc (OTC: WBCL), Worldwide Wireless Networks Inc (OTCBB: WWWNQ), and ZAP (OTCBB: ZAPZ).

For up-to-the-minute news, features and links click on www.financialwire.net

FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on www.investrend.com/contact.asp

The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: www.investrend.com/XmlFeeds?level=268

URL: www.financialwire.net

(C) 2004 financialwire.net, Inc. All rights reserved.

-0-

By: allenadvrlong

25 Jan 2004, 09:04 AM EST

Msg. 136273 of 136422
Jump to msg. #

LArry/Board-2 0f 2--here is the death blow.Just out
---------------------------------------------------

Naked shorting has now been effectively closed,

NEW YORK (Dow Jones)--Taking most market participants by surprise, the
National Association of Securities Dealers has drastically tightened one of
its rules governing short selling.

Known as affirmative determination, the NASD rule stipulates that brokers
and dealers engaged in a short sale transaction must make sure that shares
can be delivered by settlement time, three days later.

"We closed a loophole," said Steve Luparello, executive vice president of
Market Regulation at NASD.

Until now, non-NASD members, like specialists, option markets and foreign
brokers, weren't covered under the affirmative determination rule. That
means that non-NASD members didn't have to represent to the NASD broker
through which they conducted a short sale order that they would be able to
deliver the stock by settlement date.

A short seller typically borrows stock from a broker to sell it into the
market, betting that the share price will fall so that he can buy the stock
back at a lower price and pocket the difference.

The amended NASD affirmative determination rule, which was recently approved
by the Securities and Exchange Commission, will particularly affect short
sales conducted through foreign brokers, most specifically Canadian brokers
which have often been used by investors to sell short the stock of small
U.S. companies trading on the Over-the-counter Bulletin Board or OTCBB.

Because it's often impossible to borrow the shares of companies trading on
the OTCBB, investors and hedge funds looking to take negative bets on these
often-overvalued development-stage companies have traditionally been trading
through Canada where it's not required to borrow stock before selling it
short. The practice is known as naked shorting.

That trading avenue has now been effectively closed.

The new NASD rule doesn't cover Canadian brokers, since most are not members
of the association, instead it makes it the responsibility of U.S. brokers
trading with non-members to make sure that their counterparts will be able
to settle a transaction before completing a short sale.

"It's part of (a broker's) supervisory responsibilities," NASD's Luparello
said, adding that a non-member's previous failures to deliver should be a
good indication of whether or not it will in fact be able to complete the
transaction by the settlement date.

Market makers engaged in bone fide market making activities will continue to
be exempt from affirmative determination.

Luparello said that, unlike a parallel SEC initiative to tighten short
selling rules on the small-cap markets, the new NASD rules did not originate
from worries over mounting failures to deliver stock into the national
clearing system. But Luparello said the amended NASD rule fits nicely with
the new short selling regulations now under consideration by the SEC.

"I think it addresses a gap and (shows) that we, like the SEC, are looking
at a variety of things in this area," Luparello said.

The NASD proposal was first submitted to the SEC in November 2001, well
before alleged abuses of naked shorting became the focal point of a campaign
lead by some OTCBB companies in the U.S that say they have been victimized
by the practice.

While some investors argue that short sellers provide a needed service to
the markets, others have called for the complete abolition of short selling
because of the undue pressure its puts on the shares of companies.

While market participants in the U.S. and abroad are well aware of the new
short selling regulations being put forward by the SEC, known as Regulation
SHO, most said they knew nothing of the NASD's plan before it became final.

"It's taken us by surprise," said Richard Thomas, head of compliance at
Canadian brokerage firm Pacific International.

Although separate from it, the amended NASD rule fits tightly within the
SEC's SHO which is now under review by the SEC staff after a period during
which market participants were invited to comment on it.

As it stands, the new SEC short selling rules will make it easier to short
large-cap stocks since they would do away with the "uptick" rule, which bans
short selling on a stock when the price is falling.

But it when it comes to the small-cap markets, where it's often impossible
to borrow stock, the impact of SHO will be the opposite, making it harder to
short sale stock.

The new SEC rule sets a predetermined level of so-called clearing fails -
cases in which a broker or investor cannot deliver stock within two days
after settlement - which will trigger a 90-day blackout whereby the customer
will not be allowed to short sell that security. That 90-day exemption would
affect trading of U.S. securities in and outside the U.S.

The new NASD affirmative determination rule will take effect on Feb. 20.

By: gatorbak

25 Jan 2004, 12:02 PM EST

Msg. 136289 of 136426
Jump to msg. #

IN THE MONEY: NASD Tightens Short Selling/Delivery Rule

By Carol S. Remond
A Dow Jones Newswires Column

NEW YORK (Dow Jones)--Taking most market participants by surprise, the National Association of Securities Dealers has drastically tightened one of its rules governing short selling.

Known as affirmative determination, the NASD rule stipulates that brokers and dealers engaged in a short sale transaction must make sure that shares can be delivered by settlement time, three days later.

"We closed a loophole," said Steve Luparello, executive vice president of Market Regulation at NASD.

Until now, non-NASD members, like specialists, option markets and foreign brokers, weren't covered under the affirmative determination rule. That means that non-NASD members didn't have to represent to the NASD broker through which they conducted a short sale order that they would be able to deliver the stock by settlement date.

A short seller typically borrows stock from a broker to sell it into the market, betting that the share price will fall so that he can buy the stock back at a lower price and pocket the difference.

The amended NASD affirmative determination rule, which was recently approved by the Securities and Exchange Commission, will particularly affect short sales conducted through foreign brokers, most specifically Canadian brokers which have often been used by investors to sell short the stock of small U.S. companies trading on the Over-the-counter Bulletin Board or OTCBB.

Because it's often impossible to borrow the shares of companies trading on the OTCBB, investors and hedge funds looking to take negative bets on these often-overvalued development-stage companies have traditionally been trading through Canada where it's not required to borrow stock before selling it short. The practice is known as naked shorting.

That trading avenue has now been effectively closed.

The new NASD rule doesn't cover Canadian brokers, since most are not members of the association, instead it makes it the responsibility of U.S. brokers trading with non-members to make sure that their counterparts will be able to settle a transaction before completing a short sale.

"It's part of (a broker's) supervisory responsibilities," NASD's Luparello said, adding that a non-member's previous failures to deliver should be a good indication of whether or not it will in fact be able to complete the transaction by the settlement date.

Market makers engaged in bone fide market making activities will continue to be exempt from affirmative determination.

Luparello said that, unlike a parallel SEC initiative to tighten short selling rules on the small-cap markets, the new NASD rules did not originate from worries over mounting failures to deliver stock into the national clearing system. But Luparello said the amended NASD rule fits nicely with the new short selling regulations now under consideration by the SEC.

"I think it addresses a gap and (shows) that we, like the SEC, are looking at a variety of things in this area," Luparello said.

The NASD proposal was first submitted to the SEC in November 2001, well before alleged abuses of naked shorting became the focal point of a campaign lead by some OTCBB companies in the U.S that say they have been victimized by the practice.

While some investors argue that short sellers provide a needed service to the markets, others have called for the complete abolition of short selling because of the undue pressure its puts on the shares of companies.

While market participants in the U.S. and abroad are well aware of the new short selling regulations being put forward by the SEC, known as Regulation SHO, most said they knew nothing of the NASD's plan before it became final.

"It's taken us by surprise," said Richard Thomas, head of compliance at Canadian brokerage firm Pacific International.

Although separate from it, the amended NASD rule fits tightly within the SEC's SHO which is now under review by the SEC staff after a period during which market participants were invited to comment on it.

As it stands, the new SEC short selling rules will make it easier to short large-cap stocks since they would do away with the "uptick" rule, which bans short selling on a stock when the price is falling.

But it when it comes to the small-cap markets, where it's often impossible to borrow stock, the impact of SHO will be the opposite, making it harder to short sale stock.

The new SEC rule sets a predetermined level of so-called clearing fails - cases in which a broker or investor cannot deliver stock within two days after settlement - which will trigger a 90-day blackout whereby the customer will not be allowed to short sell that security. That 90-day exemption would affect trading of U.S. securities in and outside the U.S.

The new NASD affirmative determination rule will take effect on Feb. 20.

By: nvphyl

25 Jan 2004, 12:49 PM EST

Msg. 136295 of 136427
Jump to msg. #

One thing seems

clear to me. There is much OT talk about other equities. There is also much being said about political leaders. Much of that is very uncomplimentary. However, I thing the switch to these conversations instead of talking about ADVR is directly attributed to honesty. When Eli informed a tour visitor of the stark reality that the drug getting to market is a long way off, even under perfect conditions, many found it easy to drift to other subjects.

The thing that seems apparent to me is this story (Reticulous...Product R...AVR118) has a mystic. It just won't go away. On the "Road to Approval", should that ever occur, many trading opportunities should present themselves. For those that think trading is a bad thing answer this question, where would markets be without it? Once the stock is issued and brought to market and the Company receives the proceeds thereof, the trading of that equity reflects what the public currently thinks about the company. The market needs both positive and negative. It is very refreshing to hear a remark that Eli told visitors. It gives investors something to help make their decision.

The stock is selling at for about 14 cents. Here's is a couple of questions.

1) Do you think the Israeli Trial will be complete and the results know by the end of Q2 2004?

2) Do you think the results for the last 15 participants will be as good as the first 15?

3) Do you think ADVR will still be in business when the results are announced?

4) Do you recall what happened to the pps when the pre-lim results were announced?

If you can answer all those questions in the affirmative then it begs these last two questions.

5) If pre-lim results shot the pps up over triple, what will complete results do to the price?

6) Does that equal a trading opportunity?

By: lunker10706

25 Jan 2004, 01:55 PM EST

Msg. 136301 of 136428
(This msg. is a reply to 136295 by nvphyl.)
Jump to msg. #

Nvphyl: Remember the adage?

"A watched pot never boils" This is the dilemma many of us find ourselves in. You have to watch ADVR if you actively trade on the PPS ups and downs. Thats the mark of a good investor. Watch it like a hawk and pounce when the iron is hot.

Me? I bought it and hold it and pray it hits the roof!And therein lies the problem. We all hope, so we watch and watch!

Sadly, many people obsess over it.

For me, buying stocks is like betting on a football game. If you have the money to spend, go for it.

But all kidding aside, this drug, with all it's potential could be the panacea, the holy grail, the big enchilada mankind has been praying for! Thats why I'm rollin' the dice on this one.

"PRODUCT R," ADVANCED VIRAL RESEARCH CORP.'S NON-TOXIC PEPTIDE NUCLEIC ACID, INHIBITS GROWTH OF ADENOVIRUS

Findings Presented at Annual Meeting of the Infectious Diseases Society of America Demonstrate a Direct Anti-Viral Effect on Cause of Conjunctivitis and Respiratory Illness

YONKERS, NY - September 11, 2000 - Advanced Viral Research Corp. (OTCBB: ADVR) today announced that scientists from The Advanced Viral Research Institute have discovered that the company's flagship drug, "Product R," inhibits the growth of adenovirus in cell culture. Adenovirus infections cause epidemic conjunctivitis ("pink eye"), upper and lower respiratory illness and gastroenteritis. There currently is no approved, non-toxic therapy for adenoviral infections. Advanced Viral Research scientists, led by Drs. Wenlin Huang, Jin Zhang, Qingping Jiang, Yuanen Ji, John Fisher and Shalom Z. Hirschman, presented their findings at the 38th Annual Meeting of the Infectious Diseases Society of America (IDSA) in New Orleans, LA. An abstract of the findings has been published in the July issue of Clinical Infectious Diseases (Vol. 31, page 320). "The discovery by our scientists of Product R's potential impact on adenoviral infection demonstrates the rich chemistry and pharmacology of Product R," said Shalom Z. Hirschman, MD, president and CEO of Advanced Viral Research Corp. "Our research shows that Product R has a direct anti-viral effect against adenovirus. In cell culture systems, Product R inhibits adenovirus replication and viral EIA protein expression. These new findings provide the scientific rationale for our efforts to develop an ophthalmic formulation of Product R for the potential treatment of 'pink eye.'" Dr. Hirschman continued, "In addition, these findings hold promise for the large number of patients infected by adenoviruses every year and who are afflicted with conjunctivitis and respiratory and gastrointestinal illnesses. Moreover, these findings provide hope for patients with compromised immune systems who may suffer with more severe adenoviral infections such as diffuse pneumonias."
Advanced Viral Research Corp. is developing Product R as a broad-spectrum, non-toxic anti-viral drug. In both clinical and laboratory studies, Product R has also shown promise for the treatment of viral infections such as AIDS and human papilloma virus (HPV), and autoimmune diseases like rheumatoid arthritis. Advanced Viral Research Corp. laboratory studies have shown that Product R inhibits the production of both the CCR5 and CXCR4 chemokine receptors, the key cellular co-receptors for the human immunodeficiency virus (HIV). Shalom Z. Hirschman, M.D., joined Advanced Viral Research Corp. as president and CEO following a 28-year affiliation with The Mt. Sinai School of Medicine and The Mt. Sinai Hospital. He spent seven years at the National Institutes of Health in Bethesda, MD; he has been published in many peer-reviewed journals, including THE NEW ENGLAND JOURNAL OF MEDICINE, NATURE and SCIENCE, and founded one of New York City's first and most active AIDS treatment and research centers.
ABOUT ADVANCED VIRAL RESEARCH CORP.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm committed to researching, developing and bringing to market new, effective therapies for viral and other diseases, which will lead to the alleviation of human suffering and diseases worldwide. Its flagship drug, Product R, is a non-toxic peptide nucleic acid immunomodulator, with direct anti-viral effects against select viruses such as adenovirus and human papilloma virus, that has been shown to have beneficial therapeutic effects against viral diseases such as AIDS and autoimmune diseases like rheumatoid arthritis.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Product R is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries.